109年全國中等學校運動會-運動禁用藥物清單

THE WORLD ANTI-DOPING CODE

INTERNATIONAL STANDARD

PROHIBITED LIST

JANUARY 2020

ᶾ䓴忳≽䤩喍䭉⇞夷䭬

怲⊼䥨嗌㷬▕㕮⬾ⅎ⮠䔘᷽䔳怲⊼䥨嗌䮈∝䴫主∝⮁ƏḍỌ勘㕮⎱㲼㕮⇡䈯˛

勘㲼䈯㜓⥩㛰䉛姟ƏỌ勘㕮䈯䂡㹽˛Ḕ㕮䈯⥩㛰䕸侐ƏỌ勘㕮䈯䂡㹽˛ 㗪㳃⑬储 2020 ⴲ 1 㗆 1 㒣尵䏝㐆

఺䯊Ὀ⏅



JANUARY 2020

IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

ANABOLIC AGENTS

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

when administered exogenously, including but not limited to:

1-Androstenediol (5α-androst-1-ene-3β,17β-diol);

1-Androstenedione (5α-androst-1-ene-3,17-dione);

1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one);

1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one);

1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one);

4-Androstenediol (androst-4-ene-3β,17β-diol);

4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one);

5-Androstenedione (androst-5-ene-3,17-dione);

7α-hydroxy-DHEA;

7β-hydroxy-DHEA;

7-Keto-DHEA;

19-Norandrostenediol (estr-4-ene-3,17-diol);

19-Norandrostenedione (estr-4-ene-3,17-dione);

Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-

S0

S1

Calusterone;

Clostebol;

Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one);

Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol);

Drostanolone;

Epiandrosterone (3β-hydroxy-5α-androstan-17-one);

Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3- one);

Epitestosterone;

Ethylestrenol (19-norpregna-4-en-17α-ol);

Fluoxymesterone;

Formebolone;

Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol);

Gestrinone;

Mestanolone;

Mesterolone;

Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one);

Metenolone;

Methandriol;

Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one);

Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one);

Methylclostebol;

Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one);

Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-

Norclostebol (4-chloro-17β-ol-estr-4-en-3-one);

Norethandrolone;

Oxabolone;

Oxandrolone;

Oxymesterone;

Oxymetholone;

Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);

Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane);

Quinbolone;

Stanozolol;

Stenbolone;

Testosterone;

Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one);

Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

and other substances with a similar chemical structure or similar biological effect(s).

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol.

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to:

1.1 Erythropoietin-Receptor Agonists, e.g.

Darbepoetins (dEPO);

Erythropoietins (EPO);

EPO based constructs [e.g. EPO-Fc, methoxy polyeth- ylene glycol-epoetin beta (CERA)];

EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).

1.2 Hypoxia-inducible factor (HIF) activating agents, e.g.

Cobalt;

Daprodustat (GSK1278863);

Molidustat (BAY 85-3934);

Roxadustat (FG-4592);

Vadadustat (AKB-6548);

Xenon.

1.3 GATA inhibitors, e.g.

K-11706.

1.4 TGF-beta (TGF-β) signalling inhibitors, e.g.

Luspatercept;

Sotatercept.

1.5 Innate repair receptor agonists, e.g.

Asialo EPO;

Carbamylated EPO (CEPO).

S2

2. Peptide Hormones and their Releasing Factors, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing

Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin;

2.2 Corticotrophins and their releasing factors, e.g.

Corticorelin;

2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to:

Growth Hormone fragments, e.g.

AOD-9604 and hGH 176-191;

Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g.

CJC-1293, CJC-1295, sermorelin and tesamorelin;

Growth Hormone Secretagogues (GHS), e.g.

Lenomorelin (ghrelin) and its mimetics, e.g.

Anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g.

Alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin).

3. Growth Factors and Growth Factor Modulators, including, but not limited to:

Fibroblast Growth Factors (FGFs);

Hepatocyte Growth Factor (HGF);

Insulin-like Growth Factor-1 (IGF-1) and its analogues;

Mechano Growth Factors (MGFs);

Platelet-Derived Growth Factor (PDGF);

Thymosin-β4 and its derivatives e.g. TB-500;

Vascular-Endothelial Growth Factor (VEGF);

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/

degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

BETA-2 AGONISTS

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

Including, but not limited to:

Fenoterol;

Formoterol;

Higenamine;

Indacaterol;

Olodaterol;

Procaterol;

Reproterol;

Salbutamol;

Salmeterol;

Terbutaline;

Tretoquinol (trimetoquinol);

Tulobuterol;

Vilanterol.

Except:

• Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;

• Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;

• Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

S3

HORMONE AND METABOLIC MODULATORS

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to:

2-Androstenol (5α-androst-2-en-17-ol);

2-Androstenone (5α-androst-2-en-17-one);

3-Androstenol (5α-androst-3-en-17-ol);

3-Androstenone (5α-androst-3-en-17-one);

4-Androstene-3,6,17 trione (6-oxo);

Aminoglutethimide;

Anastrozole;

Androsta-1,4,6-triene-3,17-dione (androstatrienedione);

Androsta-3,5-diene-7,17-dione (arimistane);

Exemestane;

Formestane;

Letrozole;

Testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to:

Bazedoxifene;

Ospemifene;

Raloxifene;

Tamoxifen;

Toremifene.

3. Other anti-estrogenic substances including, but not limited to:

Clomifene;

Cyclofenil;

Fulvestrant.

4. Agents preventing activin receptor IIB activation including, but not limited, to:

Activin A-neutralizing antibodies;

Activin receptor IIB competitors such as:

S4

5. Metabolic modulators:

5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);

5.2 Insulins and insulin-mimetics;

5.3 Meldonium;

5.4 Trimetazidine.

DIURETICS AND MASKING AGENTS

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

• Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.

• Acetazolamide; amiloride; bumetanide; canrenone;

chlortalidone; etacrynic acid; furosemide; indapamide;

metolazone; spironolactone; thiazides, e.g. Bendroflu- methiazide, chlorothiazide and hydrochlorothiazide;

triamterene and vaptans, e.g. Tolvaptan.

Except:

• Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. Dorzolamide, brinzolamide);

• Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction

S5

PROHIBITED METHODS

MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen.

Including, but not limited to:

Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.

Including, but not limited to:

Sample substitution and/or adulteration, e.g. Addition of proteases to Sample.

2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M1

M2

GENE AND CELL DOPING

The following, with the potential to enhance sport performance, are prohibited:

1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

2. The use of normal or genetically modified cells.

M3

IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION:

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION

PROHIBITED SUBSTANCES

STIMULANTS

All stimulants, including all optical isomers, e.g.

d- and l- where relevant, are prohibited.

Stimulants include:

a: Non-Specified Stimulants:

Adrafinil;

Amfepramone;

Amfetamine;

Amfetaminil;

Amiphenazole;

Benfluorex;

Benzylpiperazine;

Bromantan;

Clobenzorex;

Cocaine;

Cropropamide;

Crotetamide;

Fencamine;

Fenetylline;

Fenfluramine;

Fenproporex;

Fonturacetam [4-phenylpiracetam (carphedon)];

Furfenorex;

Lisdexamfetamine;

Mefenorex;

Mephentermine;

Mesocarb;

Metamfetamine(d-);

p-methylamfetamine;

Modafinil;

Norfenfluramine;

S6

Including, but not limited to:

3-Methylhexan-2-amine (1,2-dimethylpentylamine);

4-Methylhexan-2-amine (methylhexaneamine);

4-Methylpentan-2-amine (1,3-dimethylbutylamine);

5-Methylhexan-2-amine (1,4-dimethylpentylamine);

Benzfetamine;

Cathine**;

Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone;

Dimetamfetamine (dimethylamphetamine);

Ephedrine***;

Epinephrine**** (adrenaline);

Etamivan;

Etilamfetamine;

Etilefrine;

Famprofazone;

Fenbutrazate;

Fencamfamin;

Heptaminol;

Hydroxyamfetamine (parahydroxyamphetamine);

Isometheptene;

Levmetamfetamine;

Meclofenoxate;

Methylenedioxymethamphetamine;

Methylephedrine***;

Methylphenidate;

Nikethamide;

Norfenefrine;

Octodrine (1,5-dimethylhexylamine);

Octopamine;

Oxilofrine (methylsynephrine);

Pemoline;

Selegiline;

Sibutramine;

Strychnine;

Tenamfetamine (methylenedioxyamphetamine);

Tuaminoheptane;

and other substances with a similar chemical structure or similar biological effect(s).

Except:

• Clonidine;

• Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*.

* Bupropion, caffeine, nicotine, phenylephrine,

phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances.

** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

NARCOTICS

The following narcotics, including all optical isomers, e.g.

d- and l- where relevant, are prohibited:

Buprenorphine;

Dextromoramide;

Diamorphine (heroin);

Fentanyl and its derivatives;

Hydromorphone;

Methadone;

Morphine;

Nicomorphine;

Oxycodone;

Oxymorphone;

Pentazocine;

Pethidine.

CANNABINOIDS

All natural and synthetic cannabinoids are prohibited, e.g.

• In cannabis (hashish, marijuana) and cannabis products

• Natural and synthetic tetrahydrocannabinols (THCs)

• Synthetic cannabinoids that mimic the effects of THC

Except:

• Cannabidiol.

GLUCOCORTICOIDS

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

Including but not limited to:

Betamethasone;

Budesonide;

Cortisone;

Deflazacort;

Dexamethasone;

S7

S8

S9

2020 年禁藥清單 Anti-Doping Commission, Chinese Taipei Olympic Committee

2020 年禁藥清單 中華奧會運動禁藥管制組譯

Selegiline;

Sibutramine;

Strychnine;

Tenamfetamine

(methylenedioxyamphetamine);

Tuaminoheptane;

及其他有相似化學結構或生物作用之物 質。

下列不在禁用之列：

• Clonidine

• 經皮膚、鼻腔、眼睛給予的imidazole 衍生物，及2020年監控計畫*所列興 奮劑。

* Bupropion, caffeine, nicotine, phenylephrine,

phenylpropanolamine, pipradrol 及 synephrine：這些物質列入2020年 監控計畫，不視為

。

** 去甲假麻黃鹼：如尿液中濃度高 於每毫升5微克，視為禁用物質。

*** 麻黃素及甲基麻黃素：如尿液中 濃度高於每毫升10微克，視為禁 用物質。

**** 腎上腺素：局部施用如鼻用、眼 用，或腎上腺素與局部麻醉劑併 用時，不在禁止之列。

***** 假麻黃鹼：如尿液中濃度高於每 毫升 150 微克，視為禁用物質。

S7 麻醉性止痛劑

下列麻醉性止痛劑，包括所有相關光學 異構體，例如

及

，均禁止使 用：

Buprenorphine;

Dextromoramide;

Diamorphine (heroin);

Fentanyl 及其衍生物;

Hydromorphone;

Methadone;

Morphine;

Nicomorphine;

Oxycodone;

Oxymorphone;

Pentazocine;

Pethidine.

S8 大麻鹼素

所有自然和合成的大麻鹼素均被禁止，

例如：

• 大麻類植物中存在的物質，例如：

hashish 及 marijuana

• 自然和合成大麻素，合成四氫大麻酚 (THC)

• 其他類大麻活性物質

下列不在禁用之列：

• 大麻二酚

S9 腎上腺皮質素

所有腎上腺皮質素均禁止以口服、靜脈 注射、肌肉注射或經直腸方式使用。

包括但不僅限於下列：

Betamethasone;

Budesonide;

Cortisone;

Deflazacort;

Dexamethasone;

Fluticasone;

Hydrocortisone;

Methylprednisolone;

Prednisolone;

Prednisone;

Triamcinolone.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

BETA-BLOCKERS

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.

• Archery (WA)*

• Automobile (FIA)

• Billiards (all disciplines) (WCBS)

• Darts (WDF)

• Golf (IGF)

• Shooting (ISSF, IPC)*

• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

• Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.

*Also prohibited Out-of-Competition

Including, but not limited to:

Acebutolol; Labetalol;

Alprenolol; Metipranolol;

Atenolol; Metoprolol;

Betaxolol; Nadolol;

Bisoprolol; Oxprenolol;

Bunolol; Pindolol;

Carteolol; Propranolol;

Carvedilol; Sotalol;

Celiprolol; Timolol.

Esmolol;

P1

1

The following substances are placed on the 2020 Monitoring Program:

THE 2020 MONITORING PROGRAM*

1. Anabolic agents:

2. Beta-2-agonists:

3. 2-ethylsulfanyl-1H- benzimidazole (bemitil):

4. Stimulants:

5. Narcotics:

6. Glucocorticoids:

In- and Out-of-Competition: ecdysterone

In- and Out-of-Competition: any combination of beta-2-agonists In- and Out-of-Competition

In-Competition only: bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine

In-Competition only: codeine, hydrocodone and tramadol In-Competition (by routes of administration other than oral, intravenous, intramuscular or rectal) and Out-of-Competition (all routes of administration)

*The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.”

2020 禁藥清單主要變更內容及說明

2020年禁藥清單主要變更內容及說明 中華奧會運動禁藥管制組譯

賽內外皆禁用的物質與方法 禁用物質

S1 同化性物質 1. 同化性雄性荷爾蒙 (AAS)

不再將同化性雄性荷爾蒙分成 a.外生性 (exogenous) 和 b.內生性 (endogenous) 兩類，而是將其統整為同一類別。S1 內列的禁用物質沒 有更動，僅新增兩個例子 (Methylclostebol 與 1-epiandrosterone)。此 變更除了反映所有由外在給予的同化性物質都是被禁止的事實，也與其他 分類的內容不再細分為內生性與外生性的呈現方式較為一致。決定物質的 來源 (例如：無論是內生性還是外生性的)，在之前相對應的技術性文件 TD2019IRMS 或其他可應用的技術性文件 (例如：TD2019NA) 或技術 性函件中皆有記載。

2. 其他同化性物質

禁用清單上也列出 LGD-4033 另一個更常用的名稱：Ligandrol。

S2 胜肽荷爾蒙、

生長因子、相 關物質及類似 物

• 經再次評估後，氬氣 (Argon) 因不再符合禁用物質的條件，故自禁用 清單中移除。

• TGF-beta 抑制劑：更名為 TGF-beta 訊號傳遞抑制劑。增加「訊號傳 遞」以求更佳反應此物質主要的作用機轉。

S4 荷爾蒙及代謝 調節劑

雌性激素受體調節劑增加兩個例子：Bazedoxifene 與 Ospemifene。

禁用方法

M2 化學和物理性 操作

措辭有所更動係為了澄清蛋白酶可於局部或全身性治療時使用，僅目的在影 響檢體時是禁止使用的。

M3 基因及細胞禁 藥

• 除了基因的修飾以外，基因表亦可透過科技的協助來產生基因禁藥的效 果，因此 M3.1 與 M3.2 類別合併。

• 為免繁瑣條列基因表現可以被改變的各個步驟，將「轉譯的、轉譯後的 或副基因調控 (epigenetic regulation) 的基因表現」等字眼修改成

「任何機轉的基因表現」，以囊括所有基因表現的機轉。

• 新增「基因靜默」與「基因轉移」為基因禁藥的方法。

2020 禁藥清單主要變更內容及說明

• 為反映「核酸」的標準科學術語，刪除「聚合物」乙詞。

• 關於幹細胞，運動禁藥清單的問與答中重申：單純使用非轉化幹細胞 (不添加生長因子或其他荷爾蒙) 來治療傷口是沒有被禁止的，只要受傷 區域回復正常功能而沒有受到強化即可。

賽內禁用的物質及方法

S6 興奮劑 • Octodrine (1,5-dimethylhexylamine)被新增至特定興奮劑。最近在一 些飲食補給品中發現此物質。

•

S7 麻醉性止痛藥 為求明確，清單內說明所有此類物質的光學異構物都是被禁止的，也澄清了 麻醉性止痛藥的光學異構物 (像是 levomethadone) 為何是被禁用的。

S8 麻鹼素 • 更新 S8 大麻鹼素的措辭，讓字義更清晰。被禁止的成分沒有更動。所 有天然或合成的大麻鹼素，包含製作大麻的原料，都是被禁止的。天然 的 THC 和合成的 THC (例如：dronabinol) 都是被禁止的。所有有 THC 效果的合成大麻鹼素皆是被禁止的。

• 大麻二酚 (Cannbidiol, CBD) 非禁用物質。但是，運動員必須小心有些 大麻二酚的產品從大麻植物萃取時，會同時萃取出 THC，導致藥檢呈現 陽性結果。

監測計畫

• 將 Ecdysterone 納入監測計畫中係為了評估其濫用的模式與普遍程度。雖然有其他的

ecdysteroids 存在，但是大部分的資料 (尤其是關於增加運動員的表現效果方面) 和關係人評 論都是集中在 ecdysterone，因此將它列為 2020 監測計畫的物質。

• 以往的更改及說明可詳見運動禁藥清單問與答

www.wada-ama.org/en/questions-answers/prohibited-list-qa